WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced it has commenced an underwritten public offering of 3,300,000 shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Tetraphase. Tetraphase intends to use the net proceeds of the offering to fund the ongoing clinical development of eravacycline, including the potential submission of a new drug application for eravacycline with the FDA, and for working capital and other general corporate purposes.
Help employers find you! Check out all the jobs and post your resume.
